CD37

Across TCGA pan-cancer cohorts, CD37 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD37 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD37 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD37 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where CD37 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.321	0.823	.001	12	view →
LSCC	OS	Tertile	III,IV	0.916	0.504	.008	6	view →
GBM	DFS	Median	All	0.199	0.383	.036	2	view →
HNSC	DFS	Quartile	All	1.000	0.542	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD37–LUAD (OS)

Open the LUAD breakdown →